How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Review Konstantinos Arvanitakis 1,2 , Theocharis Koufakis 3 , Kalliopi Kotsa 3 and Georgios Germanidis 1,2 1 First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki,54636 Thessaloniki, Greece2 Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education(SUBRE), School of Medicine, Faculty of Health Sciences, Aristotle University of…
Λεπτομέρειες







